Assessment of Calcineurin Inhibitor-Associated Neurotoxicity in Patients with Sickle Cell Disease Receiving a Matched Sibling Donor or T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation

Introduction: Sickle cell disease (SCD) is one of the most prevalent monogenic hematological disorders leading to progressive multi-organ damage and reduced life expectancy despite a significant improvement of conventional and supportive care. Allogeneic hematopoietic stem cell transplantation (HSCT...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2018-11, Vol.132 (Supplement 1), p.2088-2088
Main Authors: Kleinschmidt, Katharina, Foell, Juergen, Schulte, Johannes, Pfirstinger, Beatrix, Troeger, Anja, Aslanidis, Charalampos, Wolff, Daniel, Edinger, Matthias, Holler, Ernst, Herr, Wolfgang, Eggert, Angelika, Corbacioglu, Selim
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Sickle cell disease (SCD) is one of the most prevalent monogenic hematological disorders leading to progressive multi-organ damage and reduced life expectancy despite a significant improvement of conventional and supportive care. Allogeneic hematopoietic stem cell transplantation (HSCT) with a matched sibling donor (MSD) represents currently the only curative treatment option, limited by a donor availability 6 months in T-haplo-SCT and
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2018-99-115988